Sustained - release microspheric gel of meloxicam: Preparation, evaluation in vitro and in vivo.

Osteoarthritis (OA) is the common form of chronic joint disease. The disease progression can affect all joints of the body, seriously affecting patients’ quality of life. The most effective clinical treatment for OA at the moment is the oral or intravenous administration of non-steroidal anti-inflam...

Descripción completa

Detalles Bibliográficos
Publicado en:Biomedical Microdevices Vol. 27; no. 2; pp. 1 - 12
Autores principales: Zheng, Peng, Wei, Yongtao, Cao, Keren, Xu, Chen, Yu, Shanshan, Liu, Yang, Li, Min, Zhang, Chunyan, Wang, Tao
Formato: Journal Article
Publicado: Springer Nature Jun2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=185646758&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 185646758
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        13872176
        ODN
      jtl: Biomedical Microdevices
      issn: 13872176
      maglogo: N
    pubinfo:
      dt: Jun2025
      vid: 27
      iid: 2
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        185646758
        10.1007/s10544-025-00753-2
        185646758
      ppf: 1
      ppct: 11
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Sustained - release microspheric gel of meloxicam: Preparation, evaluation in vitro and in vivo.
      aug:
        au:
          Zheng, Peng
          Wei, Yongtao
          Cao, Keren
          Xu, Chen
          Yu, Shanshan
          Liu, Yang
          Li, Min
          Zhang, Chunyan
          Wang, Tao
        affil: https://ror.org/0523y5c19 Shandong University of Traditional Chinese Medicine, No. 4655 Daxue Road, 250300, Jinan, Shandong, China
      sug:
      ab: Osteoarthritis (OA) is the common form of chronic joint disease. The disease progression can affect all joints of the body, seriously affecting patients’ quality of life. The most effective clinical treatment for OA at the moment is the oral or intravenous administration of non-steroidal anti-inflammatory drugs, such as meloxicam (MX). However, certain challenges associated with the conventional use of those drugs include long dosing cycles, poor patient compliance, and systemic toxic side effects, primarily gastrointestinal reactions. Joint synovial fluid mainly consists of sodium hyaluronate (HA). In recent years, HA has been developed and used to treat OA with local injections. However, it also faces the limitations of short injection cycle, frequent administration, and increases the risk of exogenous infection. In this study, a microsphere gel formulation containing PL407, HA and meloxicam microspheres was prepared and the MX-MS-Gel system showed good performance, syringeability and stability. The results of in vitro release studies showed that the MX-MS-Gel released 8.6% in vitro at 72 h and 28.0% at 480 h, with a more moderate drug release. By injecting iodoacetic acid into the knee joint of rats to establish an OA model, MX-MS-Gel significantly improved the inflammatory response of OA, while the safety of MX-MS-Gel was superior and evaluated in this study, which was safe. The results showed that MX-MS-Gel could realize the purpose of delaying the drug release rate and reducing the frequency of administration, thus improving patient compliance and medication safety.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N